Treatment details
| Variable . | HDMTX-P (n = 84 patients, 445 cycles), % . | HDMTX-T (n = 56 patients, 269 cycles), % . | Overall (n = 140 patients, 714 cycles), % . |
|---|---|---|---|
| HDMTX-containing cycles | 242 (54) | 241 (90) | 483 (68) |
| Day of HDMTX administration | |||
| Day 1 | 242 (100) | 237 (98) | 479 (99) |
| Day 2 | 0 | 3 (1) | 3 (< 1) |
| Day 8 | 0 | 1 (< 1) | 1 (< 1) |
| Cycles administered as EPOCH | 14 (3) | 7 (3) | 21 (3) |
| No. of HDMTX-containing cycles/patient | |||
| Median (range) | 3 (1-6) | 5 (1-6) | 3 (1-6) |
| 1 | 10 (12) | 7 (13) | 17 (12) |
| 2 | 5 (6) | 4 (7) | 9 (6) |
| 3 | 60 (71) | 5 (9) | 65 (46) |
| 4 | 4 (5) | 8 (14) | 12 (9) |
| 5 | 1 (1) | 11 (20) | 12 (9) |
| 6 | 4 (5) | 21 (38) | 25 (18) |
| HDMTX administration with (R)CHOP cycles | |||
| With cycle 1 | 47 (55) | 39 (70) | 86 (61) |
| With cycle 2 | 65 (76) | 45 (80) | 110 (77) |
| With cycle 3 | 66 (77) | 48 (86) | 114 (80 |
| With cycle 4 | 42 (49) | 41 (73) | 83 (58) |
| With cycle 5 | 16 (19) | 38 (68) | 54 (38) |
| With cycle 6 | 11 (13) | 32 (57) | 43 (30) |
| Cycles with IT-methotrexate | 35 (8) | 31 (12) | 66 (9) |
| Patients with IT-methotrexate ≥1 cycle | 20 (24) | 23 (41) | 43 (31) |
| Cycles with G-CSF | 371 (86) | 256 (95) | 627 (90) |
| HDMTX cycles with G-CSF | 239 (99) | 240 (100) | 479 (99) |
| Days from end of methotrexate infusion to clearance (level <0.05 µmol/L), median (range) | 3 (2-25) | 4 (2-24) | 4 (2-25) |
| Variable . | HDMTX-P (n = 84 patients, 445 cycles), % . | HDMTX-T (n = 56 patients, 269 cycles), % . | Overall (n = 140 patients, 714 cycles), % . |
|---|---|---|---|
| HDMTX-containing cycles | 242 (54) | 241 (90) | 483 (68) |
| Day of HDMTX administration | |||
| Day 1 | 242 (100) | 237 (98) | 479 (99) |
| Day 2 | 0 | 3 (1) | 3 (< 1) |
| Day 8 | 0 | 1 (< 1) | 1 (< 1) |
| Cycles administered as EPOCH | 14 (3) | 7 (3) | 21 (3) |
| No. of HDMTX-containing cycles/patient | |||
| Median (range) | 3 (1-6) | 5 (1-6) | 3 (1-6) |
| 1 | 10 (12) | 7 (13) | 17 (12) |
| 2 | 5 (6) | 4 (7) | 9 (6) |
| 3 | 60 (71) | 5 (9) | 65 (46) |
| 4 | 4 (5) | 8 (14) | 12 (9) |
| 5 | 1 (1) | 11 (20) | 12 (9) |
| 6 | 4 (5) | 21 (38) | 25 (18) |
| HDMTX administration with (R)CHOP cycles | |||
| With cycle 1 | 47 (55) | 39 (70) | 86 (61) |
| With cycle 2 | 65 (76) | 45 (80) | 110 (77) |
| With cycle 3 | 66 (77) | 48 (86) | 114 (80 |
| With cycle 4 | 42 (49) | 41 (73) | 83 (58) |
| With cycle 5 | 16 (19) | 38 (68) | 54 (38) |
| With cycle 6 | 11 (13) | 32 (57) | 43 (30) |
| Cycles with IT-methotrexate | 35 (8) | 31 (12) | 66 (9) |
| Patients with IT-methotrexate ≥1 cycle | 20 (24) | 23 (41) | 43 (31) |
| Cycles with G-CSF | 371 (86) | 256 (95) | 627 (90) |
| HDMTX cycles with G-CSF | 239 (99) | 240 (100) | 479 (99) |
| Days from end of methotrexate infusion to clearance (level <0.05 µmol/L), median (range) | 3 (2-25) | 4 (2-24) | 4 (2-25) |